Sanofi To Advance Kymera’s IRAK4 Protein Degrader After Phase I Success
But Some Analysts Advise Caution
The French major is planning a Phase II trial of KT-474 in atopic dermatitis and hidradenitis suppurativa after the asset fared well in a small Phase I trial, although some analysts remain skeptical.
